IRCT201008094541N1 IRCT 2010-10-18 Guilan University of Medical Sciences The assessment of effect of Tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia The assessment of effect of Tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia on patients treated with standard medication 2009-02-05 anticipated 132 Complete https://irct.ir/trial/4845 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 3 Benighn Prostatic Hypertrophia. Intervention 1: Placebo tablet at 10 pm every night for 12 weeks. Intervention 2: Tadalafil tablet 10mg at 10 pm every night for 12 weeks.

public Dr. Amin Afshari Moghaddam

Urology Research Center, Guilan University of Medical Sciences

Rasht Iran (Islamic Republic of) 41448-95655 +98 13 1552 5259 urc@gums.ac.ir Urology Research Center scientific Dr. Ali Roushani

Urology Research Center, Razi Hospital

Rasht Iran (Islamic Republic of) 41448-95655 +98 13 1552 5259 urc@gums.ac.ir Urology Research Center Iran (Islamic Republic of) Iran (Islamic Republic of) Iran (Islamic Republic of) Inclusion criteria: patients with score > 8 and without any indications for prostatic surgery such as recurrent retention, persistent gross hematuria, permanent urinary infections associated with BPH, renal function failure and hydronephrosis, bladder stone due to BPH, under previous standard medical treatment with prazocine (max doze 10mg) daily with or without Finastride (5 mg, daily, for 3 months). Response to medication should be in plateau level 45 years 80 years Male N40 Benign Prostatic Hypertrophia Placebo Treatment - Drugs Placebo tablet at 10 pm every night for 12 weeks Tadalafil tablet 10mg at 10 pm every night for 12 weeks International score of prostatic signs & symptoms. Timepoint: Baseline and 3 months after the intervention. Method of measurement: IPSS: International Prostatic Symptom Score. Urinary satisfaction. Timepoint: Baseline and 3 months after the intervention. Method of measurement: (IPSS: International Prostatic Symptom Score). Maximum urinary flow. Timepoint: Baseline and 3 months after the intervention. Method of measurement: Uroflometry. Guilan University of Medical Sciences Approved 2008-12-20 Guilan University of Medical Sciences Guilan University of Medical Sciences Rasht Iran (Islamic Republic of)